Vivos Agrees to Stake and Test Co-Ownership With SOD Sciences

Vivos Therapeutics has entered into a definitive agreement involving SOD Sciences and its pseudohypoxia early-warning diagnostic test, according to Medical Device Network.

Medical Device Network reported that the agreement provides Vivos with an 11% fully diluted equity interest in SOD Sciences. It also provides Vivos with a 50% undivided co-ownership stake in the pseudohypoxia early-warning diagnostic test.

Agreement combines company and test interests

The reported transaction includes two distinct elements: an equity interest in SOD Sciences and a co-ownership stake in its diagnostic test. Medical Device Network identified the equity component as an 11% fully diluted interest in SOD Sciences.

Separately, Vivos is set to hold a 50% undivided co-ownership stake in the pseudohypoxia early-warning diagnostic test, Medical Device Network reported. The publisher described the arrangement as part of a definitive agreement.

The report names Vivos Therapeutics and SOD Sciences as the parties connected to the agreement. It identifies the asset at the center of the co-ownership arrangement as a pseudohypoxia early-warning diagnostic test.

Diagnostic test is central to the transaction

For laboratory and medical diagnostic sales professionals, the announcement concerns the ownership structure around a diagnostic testing product. Medical Device Network’s report distinguishes the interest in SOD Sciences from the co-ownership position in the pseudohypoxia test.

The 11% fully diluted equity interest applies to SOD Sciences, while the 50% undivided stake applies to the pseudohypoxia early-warning diagnostic test, according to Medical Device Network. Those reported details define the announced agreement.

Commercial teams following diagnostic industry transactions can note the separate company and product components described in the report. Medical Device Network did not provide additional details in the supplied report about the test beyond its identification as a pseudohypoxia early-warning diagnostic test.

Reported transaction details

• Vivos Therapeutics entered into a definitive agreement, according to Medical Device Network.
• The agreement includes an 11% fully diluted equity interest in SOD Sciences.
• It includes a 50% undivided co-ownership stake in the pseudohypoxia early-warning diagnostic test.
• Medical Device Network described the product as a pseudohypoxia early-warning diagnostic test.